- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA granted IND clearance for Flare Therapeutics Inc.'s prioritized programs.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted IND clearance for Flare Therapeutics Inc.'s prioritized programs.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA provided guidance for HCW Biologics' IND application.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A company involving Oxford seeks FDA clearance for a new diagnostic test.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA approval expands patient access to therapies for ACCORD.